Clinical trials: Mild Alzheimer Disease
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (NMI)
The proposed study is designed to evaluate the performance of the ALTOIDA™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Disorders, Cognitive Impairment
- Trial name
- AltoidaML (NCT02843529)
- Testing
- Altoida: neuropsychological, MRI, EEG and CSF biomarkers
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Altoida
Cognitive Impairment, Dementia
COcoa Supplement and Multivitamin Outcomes Study for the Mind
The parent trial (COcoa Supplement and Multivitamin Outcomes Study, COSMOS; NCT02422745) is a randomized clinical trial of cocoa extract supplement (containing a total of 500 mg/d flavanols, including 80 mg.
- Conditions
- Cognitive Impairment, Dementia, Aging
- Trial name
- COSMOS-Mind (NCT03035201)
- Where
- United States
- Volunteers
- 2,262 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Polypharmacy, Alzheimer's Disease and Related Dementias
ALIGN: Aligning Medications With What Matters Most (Demonstration)
The goal of this clinical trial is to test the effectiveness of a pharmacist-led, primary care-based de-prescribing intervention for people living with dementia (PLWD) and the person's care partners.
- Conditions
- Polypharmacy, Alzheimer's Disease and Related Dementias, Mild Cognitive Impairment
- Trial name
- NCT06335953
- Testing
- Pharmacist-led deprescribing intervention
- Where
- United States
- Volunteers
- 474 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment
This study aims to develop and evaluate new in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease, other dementias…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT04206670
- Testing
- In-Home Technology System and Questionnaires, Waiting Control In-Home Technology System and Questionnaires
- Where
- United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Mild Cognitive Impairment, Alzheimer's Disease
Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation
Remembering how to travel from one location to another is critical in everyday life, yet this vital ability declines with normal aging and can be further affected by conditions that disproportionately affect the elderly, such as…
- Trial name
- NCT01958437
- Testing
- Transcranial direct current stimulation (tDCS)
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate florbetapir (18F) positron emission tomography (PET) imaging for distinguishing Japanese healthy control subjects, from Japanese subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT01662882
- Testing
- florbetapir (18F)
- Where
- 2 sites in Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored.
- Trial name
- NCT02754830
- Testing
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Dementia
Innovations in Dementia Empowerment and Action
The lack of efficacious research-based interventions for such vulnerable older adults with Alzheimer's disease and related dementias (AD/RD) and their caregivers (CGs) is a significant public health problem.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Parkinson Disease Dementia
- Trial name
- IDEA (NCT03550131)
- Testing
- Innovations in Dementia Empowerment and Action (IDEA), Reducing Disabilities in Alzheimer's Disease (RDAD)
- Where
- United States
- Volunteers
- 322 people, healthy volunteers welcome
- Sponsor
- University of Washington
Alzheimer's Disease, Amnestic Mild Cognitive Impairment
[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)
This 2-part, open-label study was designed to investigate the safety, tolerability, and efficacy of [18F]MK-6240, a Positron Emission Tomography (PET) imaging agent, for the quantification of neurofibrillary tangle (NFT)…
- Trial name
- NCT02562989
- Testing
- [18F]MK-6240, ~185 MBq, [18F]MK-6240, ~160 MBq
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mild Cognitive Impairment, Alzheimer Disease
Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study
850,000 people live with dementia in the UK, with that number expected to rise to more than 1 million within the next 5 years. The most common type of dementia (55%) is Alzheimer's dementia, and vascular dementia is the second…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Vascular Dementia, Healthy Controls
- Trial name
- NCT03134963
- Testing
- Transcranial doppler ultrasonography, Blood pressure monitoring, Heart rate monitoring
- Where
- 2 sites in United Kingdom
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Alzheimer Disease, Mild Cognitive Impairment
Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
This study will investigate the performance of physician readers trained to read florbetapir-PET scans using electronic media training.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Trial name
- NCT01550549
- Testing
- florbetapir F 18
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild Cognitive Impairment
Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation
Patients with amnestic mild cognitive impairment (MCI) often have compromised quality of life (QOL). Cognitive impairment is a major contributor to decrements in QOL and progression of MCI often leads to loss of independence and…
- Trial name
- TVNS MCI (NCT03359902)
- Testing
- Transcutaneous vagal nerve stimulation
- Where
- 3 sites in United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of Florida
Alzheimer's Disease, Mild Cognitive Impairment
Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images
To Evaluate the Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]flutemetamol Positron Emission Tomography (PET) Images.
- Trial name
- NCT01672827
- Testing
- [18F]Flutemetamol
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Alzheimer's Disease
[18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002)
The purpose of this study is to evaluate radiolabeled [18F]MK-3328 as a PET tracer for estimating the regional distribution and extent of amyloid plaques in participants suffering from amnestic mild cognitive impairment (aMCI)…
- Trial name
- NCT01385033
- Testing
- [18F]MK-3328
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Aging, Mild Cognitive Impairment
tDCS and Cognitive Efficiency in Ageing
Normal aging is associated with a progressive decline in cognitive functions, especially memory. This decline in cognitive function can negatively impact the quality of life of older adults.
- Conditions
- Aging, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- FRtDCS (NCT05216315)
- Testing
- Transcranial direct current stimulation (tDCS)
- Where
- Spain
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Valencia
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Wearables
This study aims to develop, evaluate, and commercialize an in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT05159557
- Testing
- In-Home Technology System, Limited In-Home Technology
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Late Onset Alzheimer
Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment
Life expectancy in Brazil has increased markedly over the last 30 years. Hence, age-related disorders, such as Alzheimer's disease (AD), warrant special attention due to their high prevalence in the elderly.
- Trial name
- NINDS-AIREN (NCT02007291)
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Federal University of Minas Gerais
Mild Cognitive Impairment, Alzheimer Disease
Understanding Circadian Responses to Light in Persons With Mild Cognitive Impairment
The purpose of this research study is to investigate the relationship between light, the thickness of the pigment at the back of your eye, melatonin levels, and memory.
- Trial name
- NCT05411822
- Testing
- Lighting Intervention Blue light, Lighting Intervention Green light, Dim-light control condition
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Rural Homes
This study aims to develop, evaluate, and commercialize an in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT05159583
- Testing
- In-Home Technology System, Limited In-Home Technology
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley